Targeting Latent Tuberculosis Using Hypoxia-Activated Prodrugs of Bedaquiline Analogues
ACS Medicinal Chemistry Letters·
- DOI
- 10.1021/acsmedchemlett.6c00238
- PMID
- —
- PMCID
- —
- OpenAlex
- W7207754987
- Study type
- Journal article
- Publisher
- American Chemical Society (ACS)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings address antimicrobial resistance and limited treatment options for latent tuberculosis infection, which affects approximately 90% of infected individuals. The hypoxia-activated prodrug approach may improve treatment of persistent tuberculosis within hypoxic niches that drive prolonged treatment regimens.
Structured evidence summary
Research question
The study investigated whether nitroimidazole-based hypoxia-activated prodrugs of bedaquiline analogues could improve selective drug delivery to hypoxic tuberculosis granulomas for treating latent tuberculosis infection.
Study design
Researchers synthesized thirty-six nitroimidazole-based hypoxia-activated prodrugs and evaluated their antitubercular activity in vitro under both oxic and hypoxic conditions, along with assessment of hypoxic selectivity and trigger cleavage.
Population and setting
The study targeted Mycobacterium tuberculosis in vitro, with specific focus on hypoxic conditions that model the environment within latent tuberculosis granulomas.
Main findings
The hypoxia-activated prodrugs demonstrated potent activity against tuberculosis under both oxic and hypoxic conditions, with consistently lower minimum inhibitory concentrations in hypoxic assays. Enhanced trigger cleavage under hypoxic conditions provided evidence for hypoxia-selective activation of these compounds.
Public-health relevance
The findings address antimicrobial resistance and limited treatment options for latent tuberculosis infection, which affects approximately 90% of infected individuals. The hypoxia-activated prodrug approach may improve treatment of persistent tuberculosis within hypoxic niches that drive prolonged treatment regimens.
Important limitations
This summary relies on the supplied single-article abstract and metadata. The study reports in vitro findings only; translation to clinical efficacy, safety, pharmacokinetics, and performance in animal models or human subjects requires evaluation of the original paper.
GIDS interpretation
The article was identified through classifier links for Tuberculosis, Antimicrobial resistance, and Treatment, reflecting its focus on drug development for latent tuberculosis infection and resistance challenges. This summary describes the supplied article only and does not constitute surveillance data or signal confirmation.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 6 auditable classifier relationships to diseases, places, topics, and study design.